제품 수집
제품 세부정보
Synonyms
IMD67, IPD1, IRAK-4, NY-REN-64, REN64
Source
Human IRAK4 Protein, GST Tag (IR4-H5533) is expressed from Baculovirus-Insect cells. It contains AA Asn 2 - Ser 460 (Accession # Q9NWZ3-1).
Predicted N-terminus: Met
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a GST tag at the N-terminus.
The protein has a calculated MW of 76.9 kDa. The protein migrates as 70-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 300 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
SDS-PAGE
Human IRAK4 Protein, GST Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC
The purity of Human IRAK4 Protein, GST Tag (Cat. No. IR4-H5533) was greater than 85% as determined by SEC-HPLC.
Bioactivity
The IRAK4 assay is performed using the ADP-Glo TM Kinase Assay kit which quantifies the amount of ADP produced by the IRAK4 reaction. The ADP- Glo TM Reagent is added to terminate the kinase reaction and to deplete the remaining ATP, and then the Kinase Detection Reagent is added to convert ADP to ATP and to measure the newly synthesized ATP using luciferase/luciferin reaction. The specific activity is >15 pmol/min/μg (QC tested).
Protocol
사용자 리뷰 댓글 남기기
배경 소개
프론티어 진행
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
